Thanks to people such as Eric Lefkofsky, the fight against cancer has become more effective. In recent years, cancer has become an ongoing battle in America. In fact, it remains as relevant as America’s fight against terrorism. With that being said, cancer does not discriminate. Each year, people from all walks of life succumb to the perils of having cancer. Fortunately, there remains a glimmer of hope. Around the clock, scientists and researchers work tirelessly to devise a cure that will save the lives of millions. Moreover, few people remain as dedicated as Eric Lefkofsky.
For those unaware, Eric Lefkosky remains a man of praise and honor. Not only did he create the insanely successful business Groupon, he also developed a company aimed at fighting cancer. Moreover, the name of the company remains Tempus. Due to Eric’s goal of bringing change to cancer patients, Tempus remains extremely inclusive regarding the latest trends in technology. Furthermore, the company created its own operating system to fight cancer. In addition, Eric Lefkofsky remains the founder of Lightbank. Lightbank remains an investment company rooted in disruptive technologies and learn more about Eric.
Although many people may wonder why Eric Lefkofsky delved into finding cures for cancer, the answer remains simple. Eric remains dedicated to finding a cure for his wife’s breast cancer. Therefore, she remains fighting for her life. In addition, Lefkofsky created a foundation in honor of her. The name of the foundation remains the Lefkofsky Family Foundation. Also, Lefkofsky serves numerous positions at other cancer-fighting agencies. Moreover, Lefkofsky hails from an educated background.
Therefore, he possesses the credentials necessary to research and create cures for cancer. Moreover, Lefkofsky remains an esteemed graduate of the University of Michigan. In addition, he earned his Juris Doctor at the University of Michigan Law School. Recently, Tempus provided details regarding their partnership with the University of Chicago Medicine. Moreover, the partnership remains focused on analyzing cancer patients and creating a treatment plan for them. Moreover, the company stated that they will analyze data retrieved from about 1,000 breast cancer patients. Therefore, they will know how cancer patients respond to their treatment.
More visit: www.forbes.com/profile/eric-lefkofsky
Oncotarget serves an important function the medical research field. It covers research on all the aspects of oncology research. This peer-reviewed publication is a must have for all medical professional researching ways to combat the ravages of cancers attacking the human organism. The journal was first started in 2010 and is published by Impact Journals. Mikhail Blagosklonny and Andrei V. Gudkov are the editors-in-chief of this valuable weekly publication. The journal is peer reviewed and is published by Impact Journals.
There is a community of cancer researchers that is dedicated to finding cures and advancing the knowledge about cancer that is being discovered by different groups around the world. Efforts like Oncotarget serve to advance the fight against all types of cancers by spreading knowledge through the medical community. The information contained within the pages of Oncotarget is targeted at scientists and researchers, and not for the general public. The level of information is at a very advanced stage and is undecipherable by the general reading public. Oncotarget is also available on Dove Press.
Mikhail Blagosklonny was educated in Russia and currently is a professor of Oncology at the prestigious Roswell Park Cancer Institute in Buffalo, New York. He continues his quest for cures and treatments fighting cancer.
Andrei V. Gudkov shares the responsibility of this weekly cancer research edition. He also is working as a cancer researcher connected to the Roswell Park Cancer Institute in Buffalo.
These two valiant men are fighting the greatest enemy of man. Their efforts or those of their successors will eventually lead to the termination of cancers in the human body and will save countless suffering.
According to the findings of new clinical studies, the administration of high dose immunosuppressive therapy, accompanied by transplantation of an individual’s blood-forming stem cells, has the potential to induce sustained remission of the autoimmune disease – multiple sclerosis.
In a clinical trial that was sponsored by the National Institute of Allergy and Infectious Diseases, 69 percent of the participants exhibited decreased progression of disability and reduced relapses of the symptoms of multiple sclerosis. Upon receiving HDIT/HCT, the trial participants did not take any other MS medications. Based on this study, and numerous others, MS drugs portray lower success rates. On the other hand, the extended findings of this study suggest that a single treatment using HDIT/HCT is more effective compared to long-term treatments using the best medications available to people suffering from a given type of MS, as explained by the director of NIAID, Anthony S. Fauci, M.D.
The primary objective of the experimental treatment is to suppress active disease, and also prevent further disability into ways; by eliminating the disease-causing cells, and by resetting the immune system. The doctors collect the blood-forming cells of the participant, administer to the participant high dose chemotherapy to expand the immune system and then return the stem cells of the participant to stimulate reconstruction of the immune system. Richard Nash, M.D, Colorado Blood Cancer Institute and Presbyterian St. Luke Hospital, believes that the results of the five-year clinical trial offer a promise for long-term treatment, even though more research may be needed. If larger studies confirm these findings, HDIT/HCT might just be the therapeutic option that patients who have relapsing-remitting multiple sclerosis, have been waiting for.
About Dr. Shiva Gopal Vasishta
An M.D, Shiva Gopal Vasishta is a practicing neurologist in Voorhees, New Jersey. He has been practicing for 40 years. He studied at Government Medical College in 1979 and finished his residency at Boston City Hospital. Shiva Gopal Vasishta also practices psychiatry. Presently, he is practicing at Neurodiagnostic Associate, besides having an affiliation with Kennedy Health System Cherry Hill Campus.
Dr. Shiva Gopal Vasishta has the necessary licensing that permits him to work in New Jersey. The fact that he participates in Medicare programs means that he accepts the amount of money approved by Medicare without billing patients additional payments. Shiva Gopal Vasishta is board certified in neurology and avails his services in both English and Spanish.